Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1945 studies found for:    ( "December 1, 2011" : MAX ) [FIRST-RECEIVED-DATE] AND (lymphoma OR CLL [CONDITION ]) AND NOT myeloma [CONDITION]
Show Display Options
Rank Status Study
1 Recruiting Brazilian Network for Lymphoma Registry
Condition: Lymphoma
Intervention: Other: Observational, non-intervention
2 Recruiting MRI Compared to PET/CT for Staging and Treatment Response in Lymphoma
Condition: Lymphoma
Interventions: Device: magnetic resonance imaging;   Device: positron emission tomography/computed tomography;   Radiation: fludeoxyglucose F 18
3 Recruiting Clinical Cohort of Lymphoma Patients in Malawi
Conditions: Lymphoma;   Hematologic Malignancies
Intervention:
4 Terminated Multicentre Registry of Treatments and Outcomes in Patients With Chronic Lymphocytic Leukaemia (CLL) Or Indolent Non Hodgkin's Lymphoma (iNHL)
Conditions: Indolent Non Hodgkin's Lymphoma (iNHL);   Chronic Lymphocytic Leukaemia (CLL)
Intervention:
5 Active, not recruiting A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Conditions: Small Lymphocytic Lymphoma;   Chronic Lymphocytic Leukemia
Interventions: Drug: ABT-199;   Drug: Rituximab
6 Unknown  Samsung Medical Center-Lymphoma Cohort Study-II
Condition: Lymphoma
Intervention:
7 Completed Molecular and Whole-body MR Imaging in Lymphomas
Conditions: Lymphoma;   Hodgkin Disease;   Lymphoma, Non-Hodgkin
Intervention: Other: 68Ga-DOTANOC PET/CT; Diffusion weighted MRI
8 Active, not recruiting An Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (PCI-32765 Versus Chlorambucil)
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Other: Arm A - Post-Chlorambucil Therapy Follow-up;   Drug: Arm B - PCI-32765;   Drug: Second-line PCI-32765;   Drug: Alternative Anticancer Treatment
9 Recruiting Non-interventional Study on TEAM Conditioning in Patients With Lymphoma (TEAM)
Condition: Lymphoma
Intervention:
10 Completed
Has Results
A Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (RESONATE™-2)
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Chlorambucil
11 Completed
Has Results
Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia
Conditions: Indolent Non-Hodgkin's Lymphoma;   Chronic Lymphocytic Leukemia
Interventions: Drug: Bendamustine at a dose of 100 mg/m2;   Drug: Bendamustine at a dose of 120 mg/m2
12 Recruiting Trial of Hu5F9-G4 in Combination With Rituximab in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Conditions: Lymphoma, Non-Hodgkin;   Lymphoma, Large B-Cell, Diffuse;   Indolent Lymphoma
Interventions: Drug: Hu5F9-G4;   Drug: Rituximab
13 Recruiting Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Lenalidomide;   Drug: Rituximab
14 Not yet recruiting Cell-free Circulating DNA in Primary Cutaneous Lymphomas
Conditions: Mycosis Fungoides;   Lymphoma, Large B-cell, Diffuse
Intervention: Genetic: Cytogenetic and molecular studies
15 Active, not recruiting the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)
Condition: Lymphoma, Large B-Cell, Diffuse
Intervention: Biological: Anti-CD19 CAR-T cells and Anti-CD20 CAR-T cells
16 Not yet recruiting Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma
Condition: Lymphoma
Interventions: Drug: Palifermin;   Drug: Panobinostat;   Drug: Gemcitabine;   Drug: Busulfan;   Drug: Melphalan;   Drug: Rituximab;   Drug: Dexamethasone;   Drug: Caphosol;   Drug: Glutamine;   Other: Oral Cryotherapy (ice chips);   Drug: Pyridoxine;   Biological: Stem Cell Infusion;   Drug: G-CSF
17 Recruiting Marginal Zone Lymphoma Cohort in Korea
Condition: Lymphoma, B-Cell, Marginal Zone
Intervention: Other: Rituximab
18 Enrolling by invitation Viral Load Changes in Lymphoma Patients With HCV Infection After Chemotherapy
Conditions: Lymphoma;   Hepatitis C Antibodies;   Drug Therapy
Intervention:
19 Completed A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients
Condition: T Cell Lymphoma
Intervention: Drug: Sorafenib
20 Active, not recruiting
Has Results
A Multicenter Phase 2 Study of PCI-32765 (Ibrutinib) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion
Conditions: Chronic Lymphocytic Leukemia With 17p Deletion;   Small Lymphocytic Lymphoma With 17p Deletion
Intervention: Drug: PCI-32765

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.